|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GALT |
Gene summary for GALT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GALT | Gene ID | 2592 |
| Gene name | galactose-1-phosphate uridylyltransferase | |
| Gene Alias | GALT | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | A0A0S2Z3Y7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2592 | GALT | LZE4T | Human | Esophagus | ESCC | 7.97e-06 | 2.81e-01 | 0.0811 |
| 2592 | GALT | LZE24T | Human | Esophagus | ESCC | 4.81e-06 | 1.73e-01 | 0.0596 |
| 2592 | GALT | LZE21T | Human | Esophagus | ESCC | 8.53e-04 | 1.81e-01 | 0.0655 |
| 2592 | GALT | P2T-E | Human | Esophagus | ESCC | 3.02e-33 | 6.77e-01 | 0.1177 |
| 2592 | GALT | P4T-E | Human | Esophagus | ESCC | 2.83e-07 | 1.24e-01 | 0.1323 |
| 2592 | GALT | P5T-E | Human | Esophagus | ESCC | 5.98e-12 | 1.18e-01 | 0.1327 |
| 2592 | GALT | P8T-E | Human | Esophagus | ESCC | 1.07e-08 | 1.11e-01 | 0.0889 |
| 2592 | GALT | P9T-E | Human | Esophagus | ESCC | 1.63e-07 | 1.68e-01 | 0.1131 |
| 2592 | GALT | P10T-E | Human | Esophagus | ESCC | 7.34e-15 | 1.24e-01 | 0.116 |
| 2592 | GALT | P11T-E | Human | Esophagus | ESCC | 2.44e-09 | 2.49e-01 | 0.1426 |
| 2592 | GALT | P12T-E | Human | Esophagus | ESCC | 5.82e-15 | 3.15e-01 | 0.1122 |
| 2592 | GALT | P15T-E | Human | Esophagus | ESCC | 3.94e-04 | 9.08e-02 | 0.1149 |
| 2592 | GALT | P16T-E | Human | Esophagus | ESCC | 3.62e-17 | 2.07e-01 | 0.1153 |
| 2592 | GALT | P17T-E | Human | Esophagus | ESCC | 7.72e-08 | 1.96e-01 | 0.1278 |
| 2592 | GALT | P20T-E | Human | Esophagus | ESCC | 6.95e-04 | 1.30e-01 | 0.1124 |
| 2592 | GALT | P21T-E | Human | Esophagus | ESCC | 1.04e-19 | 2.55e-01 | 0.1617 |
| 2592 | GALT | P22T-E | Human | Esophagus | ESCC | 2.72e-23 | 2.85e-01 | 0.1236 |
| 2592 | GALT | P23T-E | Human | Esophagus | ESCC | 5.09e-15 | 1.48e-01 | 0.108 |
| 2592 | GALT | P24T-E | Human | Esophagus | ESCC | 5.85e-09 | 7.34e-02 | 0.1287 |
| 2592 | GALT | P26T-E | Human | Esophagus | ESCC | 1.33e-18 | 1.76e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003164717 | Endometrium | EEC | regulation of protein stability | 80/2168 | 298/18723 | 2.48e-13 | 5.96e-11 | 80 |
| GO:004206017 | Endometrium | EEC | wound healing | 92/2168 | 422/18723 | 1.12e-09 | 9.58e-08 | 92 |
| GO:006156412 | Endometrium | EEC | axon development | 93/2168 | 467/18723 | 9.60e-08 | 4.69e-06 | 93 |
| GO:000740912 | Endometrium | EEC | axonogenesis | 82/2168 | 418/18723 | 1.03e-06 | 3.49e-05 | 82 |
| GO:005067315 | Endometrium | EEC | epithelial cell proliferation | 83/2168 | 437/18723 | 3.38e-06 | 9.14e-05 | 83 |
| GO:005067814 | Endometrium | EEC | regulation of epithelial cell proliferation | 72/2168 | 381/18723 | 1.76e-05 | 3.33e-04 | 72 |
| GO:005067913 | Endometrium | EEC | positive regulation of epithelial cell proliferation | 43/2168 | 207/18723 | 9.53e-05 | 1.34e-03 | 43 |
| GO:000206416 | Endometrium | EEC | epithelial cell development | 45/2168 | 220/18723 | 9.73e-05 | 1.35e-03 | 45 |
| GO:004470612 | Endometrium | EEC | multi-multicellular organism process | 45/2168 | 220/18723 | 9.73e-05 | 1.35e-03 | 45 |
| GO:005090013 | Endometrium | EEC | leukocyte migration | 67/2168 | 369/18723 | 1.19e-04 | 1.59e-03 | 67 |
| GO:004599512 | Endometrium | EEC | regulation of embryonic development | 18/2168 | 64/18723 | 2.47e-04 | 2.88e-03 | 18 |
| GO:00350363 | Endometrium | EEC | sperm-egg recognition | 12/2168 | 48/18723 | 7.30e-03 | 4.15e-02 | 12 |
| GO:00064876 | Esophagus | HGIN | protein N-linked glycosylation | 17/2587 | 65/18723 | 6.04e-03 | 4.87e-02 | 17 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012505 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
| hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa0125012 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
| hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| hsa012504 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
| hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| hsa0125011 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GALT | insertion | Frame_Shift_Ins | novel | c.550_551insCTTTTCCAAGCAAAGTCTGCTCGAGGAGTCTGGT | p.His184ProfsTer30 | p.H184Pfs*30 | P07902 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| GALT | SNV | Missense_Mutation | novel | c.268N>A | p.Asp90Asn | p.D90N | P07902 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GALT | SNV | Missense_Mutation | novel | c.46G>C | p.Glu16Gln | p.E16Q | P07902 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.703) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GALT | SNV | Missense_Mutation | novel | c.877T>G | p.Ser293Ala | p.S293A | P07902 | protein_coding | deleterious(0.04) | probably_damaging(0.945) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GALT | SNV | Missense_Mutation | c.1078G>A | p.Ala360Thr | p.A360T | P07902 | protein_coding | tolerated(0.43) | benign(0.02) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| GALT | SNV | Missense_Mutation | c.566N>C | p.Val189Ala | p.V189A | P07902 | protein_coding | deleterious(0) | benign(0.088) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GALT | SNV | Missense_Mutation | c.507N>T | p.Gln169His | p.Q169H | P07902 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| GALT | SNV | Missense_Mutation | rs553769637 | c.668G>A | p.Arg223His | p.R223H | P07902 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GALT | SNV | Missense_Mutation | rs111033686 | c.413N>T | p.Thr138Met | p.T138M | P07902 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-DC-6154-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2592 | GALT | ENZYME | HyperAcute vaccine | |||
| 2592 | GALT | ENZYME | Algenpantucel-L | ALGENPANTUCEL-L | 24343588 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |